Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Neurourology and Urodynamics|May 9, 2024
Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims studyBenjamin Chastek, Adam Carrera, Christina Landis, et al.
BMC Urology|April 2, 2025
Satisfaction and persistence with vibegron in the first 6 months of overactive bladder treatment: interim results of the phase 4, real-world COMPOSUR studyRoger R Dmochowski, Eric S Rovner, Michael J Kennelly, et al.
Clinical Orthopaedics and Related Research|May 21, 2019
What Are the Uses and Limitations of Time-driven Activity-based Costing in Total Joint Replacement?Shravani Pathak, Daniel Snyder, Thomas Kroshus, et al.
Harm Reduction Journal|July 29, 2021
Substance use and overdose risk: documenting the perspectives of formerly incarcerated persons in the Fraser East region of BCCeline McCaughran-Contreras, Saranee Fernando, Mike Sikora, et al.
Movement Disorders Clinical Practice|July 17, 2018
Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose-Escalation Multicenter StudyJoseph Jankovic, Daniel Truong, Atul T Patel, et al.
BMC Urology|April 24, 2023
Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladderRoger R Dmochowski, Eric S Rovner, Michael J Kennelly, et al.
Plos Biology|February 5, 2019
Structural basis of DSF recognition by its receptor RpfR and its regulatory interaction with the DSF synthase RpfFEvan J Waldron, Daniel Snyder, Nicolas L Fernandez, et al.
Journal of the American Academy of Dermatology|December 4, 2019
DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)Vince Bertucci, Nowell Solish, Joely Kaufman-Janette, et al.
Journal of Comparative Effectiveness Research|December 3, 2025
Health outcomes and costs in patients prescribed anticholinergic medications for overactive bladderHolly E Richter, Benjamin Chastek, Adam Carrera, et al.
Mbio|August 15, 2019
Pseudomonas aeruginosa Interstrain Dynamics and Selection of Hyperbiofilm Mutants during a Chronic InfectionErin S Gloag, Christopher W Marshall, Daniel Snyder, et al.
Pageof 3